SMURF Feasibility Study of Nasal Photodisinfection Presented at National Respiratory Conference Ondine Biomedical Inc. ("Ondine"), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, announces that results from the SMURF feasibility pilot study ("Suppression of Microbial Burden to Reduce Pneumonia in Critical Illness") were presented at the [...]

Pioneering research from Royal Columbian Hospital Foundation shows a significant decrease in pneumonia rates and establishes a new benchmark for ICU infection prevention. Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that Royal Columbian Hospital Foundation (“RCHF”)’s Advancing Innovation in Medicine (“AIM”) Research Team, at one of Canada’s leading [...]